$SRPT
Sarepta Therapeutics, Inc.
Runway:10 mo
NasdaqMarket cap: —CIK 0000873303
Upcoming catalysts
0 surfacedNo catalysts surfaced for SRPT yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06606340 | Eteplirsen | — | Enrolling By Invitation | 2033-12-31 |
| NCT05967351 | delandistrogene moxeparvovec | Phase 3 | Enrolling By Invitation | 2033-10-31 |
| NCT06952686 | SRP-9005 | Phase 3 | Withdrawn | 2030-11-30 |
| NCT04475926 | — | — | Active Not Recruiting | 2030-09-05 |
| NCT06270719 | Standard of Care | — | Enrolling By Invitation | 2029-12-31 |
| NCT05876780 | SRP-9003 | Phase 1 | Active Not Recruiting | 2028-08-28 |
| NCT04626674 | delandistrogene moxeparvovec | Phase 1 | Recruiting | 2027-12-31 |
| NCT07536061 | SRP-1005 | Phase 1 | Recruiting | 2027-11-30 |
| NCT05881408 | delandistrogene moxeparvovec | Phase 3 | Active Not Recruiting | 2027-05-31 |
| NCT07542314 | elevidys | Phase 4 | Not Yet Recruiting | 2027-03-31 |
| NCT03992430 | Eteplirsen | Phase 3 | Active Not Recruiting | 2026-10-31 |
| NCT06241950 | imlifidase | Phase 1 | Terminated | 2025-10-10 |
| NCT06597656 | delandistrogene moxeparvovec | Phase 1 | Terminated | 2025-08-05 |
| NCT06747273 | SRP-9004 | Phase 1 | Terminated | 2025-06-18 |
| NCT05906251 | SRP-6004 | Phase 1 | Terminated | 2025-06-13 |
| NCT06246513 | SRP-9003 | Phase 3 | Active Not Recruiting | 2025-03-04 |
| NCT03652259 | SRP-9003 | Phase 2 | Terminated | 2025-01-14 |
| NCT02500381 | SRP-4045 | Phase 3 | Completed | 2024-11-12 |
| NCT04004065 | Vesleteplirsen | Phase 2 | Terminated | 2023-10-30 |
| NCT05096221 | delandistrogene moxeparvovec | Phase 3 | Completed | 2023-10-04 |